Novartis Drug Pelacarsen Fails Key Lp(a) Heart Trial
By @sharedot · · 8 pages
- Health
- Cardiovascular
- Pharma
- Clinical Trials
Novartis' pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or CV death in the 8,323-patient Lp(a)HORIZON Phase 3 trial.
A Pioneering Outcomes Trial Comes Up Short
Novartis announced on September 4, 2026 that its Phase 3 Lp(a)HORIZON trial of pelacarsen, an antisense oligonucleotide developed with Ionis Pharmaceuticals, did not meet its primary endpoint.
The drug achieved lower lipoprotein(a) levels, but the findings did not demonstrate a reduced risk of the trial's composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared with placebo.
The trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease, all of whom were already receiving guideline-directed lipid-lowering and antihypertensive therapy.
Why the Failure Is So Surprising
Elevated Lp(a) is considered an inherited, independent and causal cardiovascular risk factor, affecting roughly one in five people worldwide and nearly one-third of patients with premature cardiovascular disease.
Because of that huge potential patient population, numerous experts had told Fierce Biotech that drugs lowering the 'diabolical' molecule could become blockbusters.
The Evidence From 8,323 High-Risk Patients
The double-blind, placebo-controlled trial evaluated the effect of pelacarsen on 4-point major adverse cardiovascular events in patients with Lp(a) of at least 70 mg/dL, with a subpopulation analysis at 90 mg/dL or higher.
Novartis chief medical officer Shreeram Aradhye said that although lower Lp(a) levels were observed, the findings did not show this translated into reduced cardiovascular risk in the overall study population.
According to STAT, pelacarsen had previously shown in earlier trials that it could drastically lower levels of Lp(a), making the outcomes miss all the more striking.
Analysts: The Mechanism May Not Be Dead
Fierce Biotech reports that William Blair analysts suggested pelacarsen may not have reduced Lp(a) enough to see an effect, noting past studies showed an average 72% reduction and Ionis said levels were similar in this trial, while rival RNA interference candidates from Amgen (olpasiran) and Eli Lilly (lepodisiran) cut levels by more than 90%.
Citi analysts said they 'would not declare the mechanism dead,' adding that greater target suppression could matter if cardiovascular benefit requires crossing a biological threshold, and that detailed data would be needed to distinguish a near-neutral result from a directional benefit that missed statistical significance.
The Stakes for Patients and the Field
With no approved targeted treatment for elevated Lp(a) and guidelines in the US and Europe recommending once-in-a-lifetime Lp(a) testing for all adults, the outcome leaves roughly 20% of the global population with an inherited risk factor that medicine cannot yet address beyond standard care.
Experts told Fierce Biotech before the readout that a HORIZON fail might slow the Lp(a) field but would be unlikely to bring it to a standstill.
Ionis cardiovascular leader Sam Tsimikas said ahead of the results, 'I don't think anybody's going to stop,' predicting Amgen and Lilly would continue regardless of HORIZON's outcome.
What Comes Next
Novartis says full results from Lp(a)HORIZON will be presented at an upcoming medical congress, where detailed data may clarify whether the overall miss concealed benefits in patient subgroups, particularly those with higher baseline Lp(a) levels.
William Blair analysts, per Fierce Biotech, see potential motivation to pursue deeper Lp(a) inhibition in a subpopulation of patients with higher baseline levels, though they still see meaningful risk to future Lp(a)-driven cardiovascular trials in light of HORIZON.
Amgen's and Eli Lilly's trials use different designs, which could still deliver a different answer on whether lowering Lp(a) prevents heart events.